Skip to content Skip to footer
Subscribe Now
Viewpoints_Matt Walz
VIEWPOINTS

PharmaShots Interview: Trialbee’s Matt Walz Shares Insight on Trialbee Honey Platform

In an interview with PharmaShots, Matt Walz, CEO at Trialbee share his views on the launch of the Trialbee Honey platform to empower patient recruitment Shots: Trialbee launched Trialbee Honey that allows to track, measure, and analyze all patient enrollment activities in clinical trials The platform is designed to address clinical research and trial barriers by using data to optimize the patient experience,…
December 22, 2021

Read more

Viewpoints_Anthony Ho
VIEWPOINTS

PharmaShots Interview: QIAGEN’s Anthony Ho Shares Insight on the US Government Contract to Boost the Production of PCR Tests for NeuMoDx Systems

In an interview with PharmaShots, Anthony Ho, Global Head of Strategic Planning for Molecular Diagnostics at QIAGEN share his views on the winner of the $3.4M US DOD contract to increase the production of COVID-19 PCR test Shots: QIAGEN has received a $3.4M contract from the US DOD in coordination with the Department of HHS to increase the production capacity for…
December 21, 2021

Read more

Viewpoints_Meghan Scanlon
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Meghan Scanlon Shares Insight on the Completion of its $1.07B Lumenis Acquisition

In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B  acquisition of Lumenis surgical business Shots: Boston Scientific reported the closing of its acquisition of the Lumenis surgical business from a BPEA affiliate for an upfront of $1.07B. The acquisition follows the Mar…
December 20, 2021

Read more

Viewpoints_Thierry Abribat
VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on the Data of AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer at Amolyt Pharma shares his views on the data from the P-I trial of AZP-3601 for the treatment of Hypoparathyroidism Shots: The P-I trial evaluates the safety, tolerability, PK, PD, and preliminary efficacy of AZP-3601 in 102 healthy volunteers including 52 in the SAD and 50 in the MAD cohorts…
December 15, 2021

Read more

Viewpoints_Neil Moat
VIEWPOINTS

PharmaShots Interview: Abbott’s Neil Moat Shares Insight on the US FDA’s Approval of Epic Plus Tissue Valves for Mitral or Aortic Valve Replacement

In an interview with PharmaShots, Neil Moat, MD, DVP Medical Affairs, Chief Medical Officer at Abbott's shares his views on the Epic Plus Tissue Valves approval for the treatment of mitral or aortic valve replacement The US FDA has approved Epic Plus & Epic Plus Supra Stented Tissue Valves to improve therapy options for patients with aortic or mitral valve…
December 14, 2021

Read more

Viewpoints_Alexander Bedenkov
VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

In an interview with PharmaShots, Alexander Bedenkov, Vice President, Medical International Region & Global Health Innovation Hubs (A.Catalyst) Network Head at AstraZeneca shares his views on the First Virtual Events in collaboration with Slush to accelerate better health outcomes through innovation Shots: The companies collaborated to launch virtual events and enhance collaboration in the healthcare sector. The event was run through AstraZeneca’s A.Catalyst Network,…
December 13, 2021

Read more

Viewpoints_Manos Perros
VIEWPOINTS

PharmaShots Interview: Entasis Therapeutics’s Manos Perros Shares Insight on the Data of Sulbactam-Durlobactam (SUL-DUR) for Carbapenem-Resistant Acinetobacter Infections

In an interview with PharmaShots, Manos Perros shares his views on the data from the P-III (ATTACK) trial of sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant acinetobacter infections Shots: The P-III ATTACK trial evaluates SUL-DUR vs colistin in 207 patients with infections caused by Acinetobacter baumannii at 95 clinical sites in 17 countries The trial met its 1EPs i.e., patients achieved non-inferiority in 28-day all-cause…
December 9, 2021

Read more

Viewpoints_Glenn Mattes
VIEWPOINTS

PharmaShots Interview: TFF Pharmaceuticals’s Glenn Mattes Shares Insights on the Thin Film Freezing Technology

In an interview with PharmaShots, Glenn Mattes, President, CEO, and Director at TFF Pharmaceuticals share his views on the thin film freezing technology for the development of vaccines and therapeutics against multiple infectious diseases including IPA Shots: The company focuses on developing and commercializing innovative drug products based on its patented TFF technology platform including the development of vaccines and therapeutics against multiple infectious…
December 8, 2021

Read more

Viewpoints_Atray Dixit
VIEWPOINTS

PharmaShots Interview: Coral Genomics’s Atray Dixit Shares Insights on the 2021 Innovation Challenge in Inflammatory Bowel Disease

In an interview with PharmaShots, Atray Dixit, Co-founder & CEO at Coral Genomics share his views on the winner of the $25K inflammatory bowel disease innovation challenge under the collaboration with Lyfebulb and Arena Shots: Lyfebulb and Arena collaborated to discover 2021 Imagining Life Without Limits Challenge to get the solutions for patients with IBD Coral Genomics was selected as…
December 7, 2021

Read more

Load more